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Editorial
The Ongoing Quest for the Holy Bone Graft
Grail: Scientific Progress, Economic
Bonanza, or Quixotic Quagmire?
The market for bone grafts continues to be ever-expanding in
products, device categories, and volumes applied. Market ana-
lysts consistently see bone graft substitutes as an investment
opportunity, quoting our increasingly aging and sicker popula-
tion and apparent disenchantment with the gold standard—
mainly iliac crest graft—as the leading driver for this ongoing
development. Spine surgery, and spine surgeons, are a major
contributor of bone graft substitute use—and there is no end in
sight as spine surgery continues to increase.
Numbers are staggering, especially as there was literally no
“market” for bone graft substitutes until the 1990’s. Recent
market analyses place the US market for bone graft substitutes
at 2.3 to 3.5 billion USD by 2017 with an increase of a billion
dollars through 2025 based on an annual composite growth rate
of over 5 %. For spine surgeons, the market array has become
an increasingly bewildering experience filled with promises
and scientific detail. The golden triangle of osteogenesis,
—induction and—conduction theoretically achievable with
autograft has so far eluded a satisfactory replication with
allografts (structural, machined, demineralized, or cell
enhanced), synthetic (glasses, ceramics, collagen, hyaluronic
acid, and BMP) and blended devices (assembled from allo-
grafts and synthetic devices). The market for autograft process-
ing and augmentation techniques (ie, bone marrow aspirates,
platelet and stem cell enrichment technologies) remains intact
without seemingly abating the appeal of allograft and synthetic
bone graft substitutes.
A fair number of articles in spine publications (Global Spine
Journal included) and elsewhere are dedicated to demonstrat-
ing the healing propensities of various graft materials with few,
if any, accepted standards to measure actual healing outcomes.
We still lack an ideal animal model—the transferability of data
to humans and their respective clinical scenarios is still doubt-
ful, and we remain unsure what radiographic and clinical out-
comes data best apply for bone graft related research.
Level 1 data is available for a number of products (2 BMP’s,
a peptide based synthetic, a bioactive glass and a demineralized
bone matrix), all leading to favorable findings in support of the
respective devices, but the ensuing lengthy and narrow
approvals process and lingering questions about efficiency of
the product lines make the likelihood that others will want to
pursue this level of research with all its sequelae increasingly
doubtful. As the variety of products and their associated per-
formance claims have risen, so have their prices—making
affordability of many of these products a real issue as hospital
administrators and third party payors have started to intervene
directly.
The health care value equation in spine surgery applies
almost nowhere more than in the selection and application of
bone graft materials and their substitutes. The implications of
autograft in terms of its contribution to patient outcomes and
complications, its donor site morbidity, and limited supply or
viability frequently receive insufficient attention of advocated
of its use.
All things considered, we are nowhere close to a resolution
of the bone graft question. The ongoing multiplication of prod-
ucts and technologies will likely continue to confuse clinical
results reporting, and real macrodata based on reoperation rates
of fusion patients over 2, 5, and 10 years in the area of previous
surgery using generally accepted radiographic and clinical
findings will remain elusive. Perhaps a stratified risk-based
approach using patient variables and combining that with avail-
able biological data may offer a more immediate help in com-
bining the best osteobiologics technology with a specific
patient’ needs.
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